×
Clene Long Term Debt 2018-2024 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Clene long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.
View More
Clene Long Term Debt 2018-2024 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Clene long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.2B
Amgen (AMGN)
$160B
Gilead Sciences (GILD)
$137.1B
Vertex Pharmaceuticals (VRTX)
$123.3B
Bristol Myers Squibb (BMY)
$113.2B
CSL (CSLLY)
$80.1B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$76.1B
Argenex SE (ARGX)
$39.3B
Alnylam Pharmaceuticals (ALNY)
$32.5B
BioNTech SE (BNTX)
$28.3B
BeiGene (ONC)
$23.9B
Biogen (BIIB)
$20.1B
Illumina (ILMN)
$15.4B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.9B
Genmab (GNMSF)
$14.7B
Incyte (INCY)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
BioMarin Pharmaceutical (BMRN)
$13.1B
Moderna (MRNA)
$13B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.4B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.3B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.2B
Repligen (RGEN)
$9.1B
Bio-Rad Laboratories (BIO.B)
$8.7B